SCHEMBL20340157

SCHEMBL20340157

N#Cc1c(-c2ccccc2)cc(=O)[nH]c1SCc1cncc(C(=O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ ACMSD Q8TDX5 15/20 0.51
▸ KMT2A Q03164 3/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ ADORA1 P30542 1/20 0.45
▸ MEN1 O00255 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ HSD11B1 P28845 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31443033 1.00 ACMSD (0.51) ACMSDKMT2AALDH1A1HPGDADORA1
SCHEMBL20339841 0.89 KMT2A (0.54) ACMSDKMT2AALDH1A1HPGDADORA1
SCHEMBL20340172 0.86 ACMSD (0.61) ACMSDKMT2AALDH1A1HPGDADORA1
SCHEMBL23183524 0.86 KMT2A (0.45) ACMSDKMT2AALDH1A1HPGDADORA1
SCHEMBL20339813 0.83 ACMSD (0.55) ACMSDKMT2AALDH1A1ADORA1MEN1
SCHEMBL30761220 0.83 ACMSD (0.65) ACMSDKMT2AALDH1A1HPGDADORA1
SCHEMBL20340158 0.83 ACMSD (0.65) ACMSDKMT2AALDH1A1HPGDADORA1
SCHEMBL24087895 0.80 ACMSD (0.45) ACMSDKMT2AALDH1A1HPGDADORA1
SCHEMBL20340155 0.79 ACMSD (0.59) ACMSDKMT2AALDH1A1HPGDADORA1
SCHEMBL20339582 0.78 KMT2A (0.64) ACMSDKMT2AALDH1A1HPGDADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145572-A1 Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Inhibitors ORSOBIO INC (US) 2025-05-08 — — US disclosed
US-11780812-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ORSOBIO, INC. (US) 2023-10-10 — — US disclosed
US-11780812-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ORSOBIO, INC. (US) 2023-10-10 — — US disclosed
US-11780812-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ORSOBIO, INC. (US) 2023-10-10 — — US disclosed
US-20210094916-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS ORSOBIO, INC. 2021-04-01 — — US disclosed
US-20210094916-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS ORSOBIO, INC. 2021-04-01 — — US disclosed
WO-2018125983-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 — — WO disclosed
WO-2018125983-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145572-A1 Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Inhibitors ACMSD, ALDH7A1, ALAD ACMSD 1/4885KMT2A 978/4885ALDH1A1 271/4885
US-20210094916-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS ALDH7A1, OTC, DDC ACMSD 8/4885KMT2A 1374/4885ALDH1A1 417/4885
US-11780812-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ALDH7A1, ACMSD, AMD1 ACMSD 2/4885KMT2A 1309/4885ALDH1A1 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback